Several lung cancer vaccination trials have shown that vaccines create effective soldiers, i. But the problem occurs when they come to the battlefield, i. Another promising area is the other vaccines in different phases of development for lung cancer patients. The MAGRIT trial confirms that vaccines are very well tolerated with mild side effects and no increase in immune-mediated disorders.
If any immunotherapeutic approach was going to work, it should have been in this setting and the results are therefore a big disappointment. MAGRIT is the most recent and largest trial of antigen specific immunotherapy using vaccines and in common with other trials could not show any improvement in efficacy.
With regard to immunotherapies we are witnessing a change, with clinical trials in lung cancer concentrating on checkpoint inhibition. J Clin Oncol. Epub May Information contained in this press release was provided by the abstracts authors and reflects the content of the studies. It does not necessarily express ESMO's point of view. The European Society for Medical Oncology ESMO is the leading European professional organisation committed to advancing the specialty of medical oncology and promoting a multidisciplinary approach to cancer treatment and care.
The ESMO international community counts more than 9, oncology professionals sharing best practices and the latest know-how in cancer treatment and care. Patients with cancer who develop breakthrough COVID remain at risk of severe outcomes despite full vaccination. New indication concerns the treatment of patients with metastatic colorectal cancer for whom due to toxicity is not possible to continue treatment with another fluoropyrimidine.
Based on current knowledge available, they address key questions on safety and efficacy of COVID vaccines, their interference with anticancer treatment, and advocate for a global strategy for the booster dose. Sub-group analyses of CheckMate part 1 provide reassurance but no definite guidance regarding standard treatment for different patient sub-groups. Results from an exploratory analysis of the IMpower trial confirm that there is a correlation between tumour-cell PD-L1 expression and disease-free survival.
Early clinical findings with the anti-claudin-6 CAR-T-cell product BNT, with or without amplifying vaccine, in patients with refractory solid tumours are promising but more data are required. Data suggest that assessing the quality as well as the quantity of tumour mutations may enhance prediction of outcomes in patients treated with immune checkpoint inhibitors. From cell-based therapies to soluble T-cell engagers and T-cell co-stimulation, early findings show novel promising strategies, although more data are needed.
Along with treatments with immune checkpoint inhibitors and cellular therapies, other immunotherapies are currently under investigation. Immunotherapy plus chemotherapy as first-line treatment choice for advanced disease without oncogene mutations, irrespective of ethnicity and PD-L1 status. The ESMO Immuno-Oncology Congress , the European platform dedicated to the development and use of immunotherapies for cancer treatment, will be held as an onsite and online congress.
The much-anticipated ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer has been published today in Annals of Oncology. Data from early clinical trials presented at the ESMO Congress suggest that new anticancer treatments are on the horizon, with a clear emphasis on precision medicine.
First concrete results presented at the ESMO Congress confirm need to promote vaccination in patients with cancer. Experts discuss a wealth of challenges and opportunities in primary cancer prevention that oncologists themselves must take on. Resources such as abstracts, presentations and webcasts from meetings can be accessed by ESMO members and conference delegates throughout all the year.
More about Meeting Resources. Courses on Medical Oncology for Medical Students. Annals of Oncology. ESMO Open. More about Journals. A range of publications that can be browsed online by all ESMO members and downloaded for offline use.
Essentials for Clinicians. Factsheet on Biomarkers. Visit the Education library. Participate in our collegial events with leaders in the field and get the chance to collaborate with prominent European cancer institutions. This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. The ESMO Examination has no legal standing since only national authorities can grant physicians the right to practice.
Successful candidates will be certified for five years. If approved, the recertification is also valid for five years. Questions cover all fields of medical oncology, including: basic elements of tumour path histology, epidemiology and biology.
Besides all cancer types, the ESMO Examination includes practice-oriented issues on diagnosis, staging, management, evaluation and prognosis of cancer patients. ESMO members and event attendees. Test yourself with our trial exam questions.
0コメント